iBio, Inc. and Fraunhofer USA Center for Molecular Biotechnology Enter Agreement to Provide Global Access for Bill & Melinda Gates Foundation Vaccines

Published: Jun 03, 2010

NEWARK, Del.--(BUSINESS WIRE)--iBio, Inc. (OTCBB: IBPM) and the Fraunhofer USA Center for Molecular Biotechnology (CMB) announced today an agreement which provides a license of iBio’s proprietary technology to CMB for the development and manufacture of Global Health Vaccines for, and financed by, the Bill & Melinda Gates Foundation.

Back to news